ENABLE
European Gram Negative Antibacterial Engine
| Coordinator | Redx Pharma Ltd ; VU University Amsterdam ; FORSCHUNGSZENTRUM BORSTEL ; NOSOPHARM ; ASTRAZENECA AB ; SERVICIO MADRILENO DE SALUD ; LATVIJAS ORGANISKAS SINTEZES INSTITUTS ; University of Liège ; Autonomous University of Barcelona ; SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT ; ST GEORGE'S HOSPITAL MEDICAL SCHOOL ; AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ; CNRS - Institut des Sciences Biologiques ; RISE Research Institutes of Sweden ; Network Rail ; BEACTICA THERAPEUTICS AB ; GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. ; Aston University ; Narodowy Instytut Leków ; REGION HOVEDSTADEN ; FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA ; Karolinska Institutet Innovations (Sweden) ; Asclepia Outsourcing Solutions BVBA ; Bioresources Technology & Engineering GmbH ; Mutabilis ; European Biotechnology Network aisbl ; Basilea Pharmaceutica International AG ; KeytoLead AB ; MPS Hamburg GmbH ; Cardiff University ; Uppsala University ; Spero Europe Limited ; Juvabis AG ; Northern Antibiotics Oy ; HELPERBY THERAPEUTICS LIMITED ; OT CHEMISTRY AB ; Inspiralis Ltd ; Molecular Devices (United Kingdom) ; THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS ; John Innes Centre ; Helmholtz-Zentrum für Infektionsforschung GmbH ; HELSINGIN YLIOPISTO ; THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD ; SP PROCESS DEVELOPMENT AB ; University of Zurich ; IT University of Copenhagen ; Biomol Informatics (Spain) ; Statens Serum Institut |
| Grant period | 2014-02-01 - 2020-01-31 |
| Funding body | European Union |
| Call number | IMI-JU-08-2012 |
| Grant number | 115583 |
| Identifier | G:(EU-Grant)115583 |